Frankfurt
28.07.26 | 08:13
0,080 Euro
+4,44 % +0,003
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.05. | NextCell Pharma AB: Interim Report first quarter 2026 | 298 | GlobeNewswire (Europe) | NextCell Pharma AB (publ) ("NextCell" or the "Company") publishes its Interim report for the first quarter 2026. The report is available on the company's website: www.nextcellpharma.com. NextCells share... ► Artikel lesen | |
| 27.05. | Nextcell Pharma AB: Nextcell Pharma AB (publ) Annual General Meeting 2026 | 282 | GlobeNewswire (Europe) | On Wednesday, 27 May 2026, the Annual General Meeting of NextCell Pharma AB (publ), reg. no. 556965-8361 ("NextCell" or the "Company"), was held. A summary of the resolutions adopted at the Annual General... ► Artikel lesen | |
| NEXTCELL PHARMA Aktie jetzt für 0€ handeln | |||||
| 06.05. | FUJIFILM Biosciences and NextCell Launch Global Research-Use Stromal Cell Platform | 3 | Contract Pharma | ||
| 06.05. | NEXTCELL PHARMA AB: NextCell and FUJIFILM Biosciences Launch New Commercial Platform Comprised of RUO Stromal Cells and Cell Culture Media | 4 | Cision News | ||
| 06.05. | FUJIFILM Biosciences and NextCell Launch New Commercial Platform Comprised of RUO Stromal Cells and Cell Culture Media | 492 | Business Wire | Collaboration results in platform to help researchers overcome challenges in MSC research NextCell-Cord RUO cells designed for delivery as cryopreserved and sold as an individual product... ► Artikel lesen | |
| 04.05. | NEXTCELL PHARMA AB: NextCell Pharma publishes Annual Report 2024/2024 | 1 | Cision News | ||
| 13.03. | NEXTCELL PHARMA AB: ProTrans Phase II COVID-19 Trial Accepted for Publication in Cytotherapy | 3 | Cision News | ||
| 03.03. | NEXTCELL PHARMA AB: NextCell Pharma presents historical quarterly figures | 2 | Cision News | ||
| 26.02. | NextCell Pharma AB: NextCell publishes Year-End Report 2024/2025 | 273 | GlobeNewswire (Europe) | NextCell Pharma AB (publ) ("NextCell" or the "Company") publishes its Year-End Report for the extended financial year September 1, 2024 - December 31, 2025. The report is available on the company's... ► Artikel lesen | |
| 17.02. | NEXTCELL PHARMA AB: NextCell Participating in JETRO's Japan Entry Acceleration Program | 1 | Cision News | ||
| 03.02. | NextCell Pharma AB: Seven-year follow-up data from ProTrans-Repeat demonstrate sustained disease-modifying effects of ProTrans in type 1 diabetes | 188 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or the "Company") today announces long-term follow-up data from the ProTrans-Repeat study showing sustained preservation of endogenous insulin production in patients with... ► Artikel lesen | |
| 21.01. | NextCell Pharma AB: NextCell provides strategic update on focused market progression, highlighting Hong Kong as gateway to the Chinese market | 191 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or the "Company") provides a strategic update on its focused market progression strategy, aimed at accelerating value creation by advancing ProTrans in adult patients... ► Artikel lesen | |
| 15.01. | NextCell Pharma AB: Six-year data demonstrate a durable disease-modifying effect of ProTrans in type 1 diabetes | 227 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or the "Company") today announces that six-year follow-up data indicate that a single infusion of ProTrans provides a long-lasting and clinically relevant preservation... ► Artikel lesen | |
| 02.12.25 | NextCell Pharma AB: NextCell initiates collaboration with OptiCell - strengthening its cell-handling operations | 222 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or "the Company") has entered into a collaboration agreement with OptiCell Solutions AB ("OptiCell") regarding the handling, freezing, storage, and transport of cell products... ► Artikel lesen | |
| 20.11.25 | NextCell Pharma AB: NextCell Pharma appoints Eric Gustafsson as new CFO | 517 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or "the Company") today announces the appointment of Eric Gustafsson as Chief Financial Officer (CFO). With extensive experience in leading financial transformations and... ► Artikel lesen | |
| 30.10.25 | NextCell Pharma AB: NextCell Pharma publishes its Interim Report 4 2024/2025 | 215 | GlobeNewswire (Europe) | NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 4 for the period June 1, 2025 - August 31, 2025. The report is available on the company's website: https://www.nextcellpharma.com/en/investorsfinancial-report.... ► Artikel lesen | |
| 18.09.25 | NextCell Pharma AB: NextCell Pharma AB announces CFO transition | 242 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or the "Company") today announces that the Company's CFO, Patrik Fagerholm, has decided to step down to take on a new assignment. Patrik will remain in his role throughout... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CG ONCOLOGY | 73,52 | 0,00 % | CG Oncology bladder cancer trial results published in Lancet | ||
| RELAY THERAPEUTICS | 18,640 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Pricing of Public Offering of Common Stock | CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies... ► Artikel lesen | |
| DYNE THERAPEUTICS | 25,630 | 0,00 % | Dyne Therapeutics Announces Pricing Of Upsized $375 Million Public Offering | ||
| KYMERA THERAPEUTICS | 110,05 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer | Dr. Rooney, former immunology leader at Johnson & Johnson, will lead clinical development strategy across Kymera's industry-leading oral immunology portfolio Jared Gollob, MD, will retire from his... ► Artikel lesen | |
| TANGO THERAPEUTICS | 26,720 | 0,00 % | How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48% | ||
| VERA THERAPEUTICS | 35,180 | 0,00 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 52,74 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants | BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 60,12 | 0,00 % | Guggenheim cuts Tarsus Pharmaceuticals stock price target to $89 | ||
| ZENAS BIOPHARMA | 32,820 | 0,00 % | Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD | - BLA submission based on positive results from Phase 3 INDIGO trial - WALTHAM, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas," "Zenas BioPharma" or the "Company") (Nasdaq:... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 36,010 | 0,00 % | Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026 | ||
| APOGEE THERAPEUTICS | 134,31 | 0,00 % | Apogee Therapeutics Aktie erreicht Rekordhoch von 134,34 USD | ||
| PRAXIS PRECISION MEDICINES | 316,02 | +0,07 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| TYRA BIOSCIENCES | 31,060 | 0,00 % | Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights | - Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -
- Interim Ph2... ► Artikel lesen | |
| ERASCA | 18,890 | +0,11 % | Erasca, Inc.: Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated... ► Artikel lesen | |
| ARRIVENT BIOPHARMA | 30,160 | 0,00 % | ArriVent BioPharma, Inc.: ArriVent BioPharma Reports First Quarter 2026 Financial Results | Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026IND clearance of ARR-002, ArriVent's dual-targeting MUC16/NaPi2b tetravalent... ► Artikel lesen |
Das Unternehmen NEXTCELL PHARMA AB kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,080 Euro und damit +4,44 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEXTCELL PHARMA AB finden Sie auf Wallstreet Online.